China FDA Calls for Comments on Key Policy Proposals

by Ropes & Gray LLP

Ropes & Gray LLP

On May 11-12, 2017, the China FDA (CFDA) issued four new draft policies for public comments, proposing further reforms in the current drug and medical device regulatory regime. The four draft policies aim to accelerate the review and approval of new drug and medical device applications (Circular No. 52), deregulate the conduct of clinical trials to encourage innovation (Circular No. 53), enhance post-market supervision throughout a product’s entire life cycle (Circular No. 54), and protect the rights of innovators (Circular No. 55). The CFDA is soliciting public comments until June 10, 2017. Further legislative initiatives will be arranged if any parts of the draft policies contradict the current CFDA regulations. These draft policies, if adopted, are likely to further streamline and accelerate the market access of innovative products and will have a far-reaching impact on China’s life sciences industry.

I. Circular No. 52 proposes the following key measures to accelerate the review and approval of new products:

  • Expedited reviews and approvals for urgently needed therapies. Drugs and devices that offer new solutions for treating life-threatening diseases or address critical unmet medical needs can be eligible for conditional approvals, as long as early and mid-stage study data can indicate their efficacy and predict their clinical values. Companies receiving conditional approvals must develop a risk management plan and initiate confirmatory post-approval study as per the requirements in the conditional approvals. Innovative drugs and devices sponsored by the National Science and Technology Major Project can be eligible for expedited review and approval.
  • Supportive regime for rare disease cures. Drugs and devices that offer new solutions for treating rare diseases, if already approved outside China, can be eligible for conditional approvals. Companies can complete the necessary stages of clinical study after receiving marketing authorizations. The health authorities will publish a catalogue of rare diseases and establish a rare disease patient registry.
  • Cross-disciplinary and professionalized review system. The technical review for new drugs and devices will be led by a team of cross-disciplinary reviewers. Each new drug and device application will be assigned to a dedicated managing reviewer, who will be responsible for scheduling consultation meetings. The CFDA will require consultation meetings at all critical milestones of clinical studies, i.e., prior to initiation of phase I, after completion of phase II (and prior to initiation of phase III), after completion of phase III, and prior to the NDA application. Consultation meetings with expert panels will also be required to deliberate important but controversial technical questions. The technical review conclusions will be published in public, with an exception of company confidential information.
  • Market access benefits. Hospitals will be encouraged to prioritize their procurement and use of new drugs with definite efficacy and reasonable prices. The government will support inclusion of innovative drugs in the basic medical insurance scheme, and the reimbursable drug list will be updated more frequently.

II. Circular No. 53 proposes the following new measures to remove certain governmental controls over clinical studies on new drugs and devices:

  • Expansion of clinical study infrastructure.
    • Currently, hospitals need to be certified by the CFDA and the National Health and Family Planning Commission in order to become qualified clinical study sites. The draft policy proposed to revoke the certification system. All medical institutions that have the necessary infrastructure to conduct clinical studies can file for record with the CFDA. The CFDA will supervise clinical study sites through rigorous clinical study audits, and will not admit data generated in those studies that fail the audits.
    • Hospitals, medical research institutions and academic institutions will be incentivized to actively participate in clinical studies and research. The capabilities and quality of clinical studies and research will be considered for hospitals’ and physicians’ performance reviews and ratings.
    • Foreign companies and research institutions will be allowed to conduct phase I new drug clinical trials in China.
  • Improvement in ethics committee reviews.
    • Currently, ethics committee (EC) review and approval is subsequent to the Center for Drug Evaluation (CDE)’s clinical trial authorization process. According to the proposed policy, companies can apply for EC review and approval in parallel to clinical trial applications, provided that the clinical study protocols are approved by the EC before the submission of clinical trial applications.
    • The proposed policy encourages mutual recognition of EC approvals. In the event of multi-center studies, the lead site’s EC approval can be used as the basis for all EC reviews. The ECs of other participating sites can directly endorse the EC approval of the lead site, without repetitive reviews.
    • In addition to hospital-affiliated ECs, the proposed policy intends to encourage the formation of regional ECs, which will be responsible for the supervision of clinical studies, qualification of investigators, and the adjudication of appeals filed by sponsors or investigators. 
  • Streamlining clinical trial approval process. Like the IND mechanism in the U.S., companies need to submit a clinical trial application to the CDE, but only need to wait for 60 working days before initiating the study, unless the CDE rejects the application or issues a deficiency notice during the 60-day period. For certain high-risk medical devices that are subject to the clinical trial approval process, the CFDA must give its review opinions within 60 working days upon receiving the clinical trial application. Applicants will be automatically approved to conduct trials if the Center for Medical Device Evaluation (CMDE) does not reject the application or issue a deficiency notice during the 60-day period.
  • Admission of foreign study data. Foreign clinical data can be admitted to support registration of drugs and medical devices in China, as long as (a) the trials comply with Chinese regulations, (b) the trials pass CFDA’s on-site audits, and (c) applicants can provide clinical data to prove that no ethnicity difference affects the product’s safety and efficacy.
  • Expanded access to investigational products. Expanded access to investigational products may be allowed in phase II and phase III trials where the drug or device (a) is intended for treating life-threatening diseases with no effective treatments, and (b) shows probable benefits in early studies. Only a limited number of patients (not exceeding the number of study subjects as per the approved protocol) at each site can have such compassionate use upon their informed consent. The safety data generated can be used to support marketing authorizations.

III. Circular No. 54 reinforces the CFDA’s determination to enhance post-approval enforcement.

  • Roll out the Marketing Authorization Holder (MAH) system. The MAH system has been piloted in 10 provinces since November 2015. MAHs are required to take all legal responsibilities for pre-clinical study, clinical studies, product manufacturing, quality of APIs and excipients, distribution, clinical use and adverse event reporting pertaining to the approved drugs. Meanwhile, contractual research, manufacturing, and service organizations (CRO, CMO, CSO, etc.) that are retained by MAHs are required to take both regulatory responsibilities by law and contractual liabilities. The CFDA is determined to roll out the MAH system nationwide.
  • Improve adverse event reporting system. The CFDA will levy the primary adverse event reporting responsibilities and post-market product evaluation duties on the MAHs. Concealment, delayed reporting, or misrepresentation will be severely punished by the CFDA.
  • Introduce regular and rigorous audits and inspections.
    • The CFDA will further strengthen its data integrity assessment of regulatory dossiers, continue its on-site audits on clinical trials, and take legal actions against data forgery (including criminal investigations by the police and prosecutors).
    • The CFDA and local FDAs will strengthen risk-based, on-site inspections and for-cause inspections for GxP compliance through the product’s life cycle, and build a professional team of inspectors through recruiting and training initiatives.
  • Regulate promotional activities. The CFDA will establish a Medical Representative Registration System, where all drug license holders will need to register their medical representatives. Medical representatives are allowed to conduct only academic promotion and technical consultation when interacting with physicians and are prohibited from engaging in drug sales.
  • Enhance the infrastructure for technical reviews. The CFDA will procure services from qualified third parties to meet the capacity requirement for drug and device reviews. In addition, the CFDA plans to establish an Electronic Common Technical Document (eCTD) system to standardize the format of electronic submissions of drug and device applications. It aims to create a database of master files for each approved drug and device. Last but not least, the CFDA will step up its efforts toward international harmonization of technical standards and hopes to achieve mutual recognition of review and approval decisions.

IV. Circular No. 55 proposes to establish a patent linkage system and improve regulatory data protection. It also reiterates the confidentiality obligations of all government employees involved in the review and approval process.

  • Establish patent linkage system. NDA applicants must submit a statement of patents pertinent to their drugs and either (i) an affidavit of non-infringement or (ii) a notice to relevant patent holders if the drugs may infringe any patents within 20 days after the submission of NDA applications. Patent holders can file infringement litigation within 20 days after receiving the notice or upon their knowledge of the CFDA’s acceptance of the NDA applications, and inform the CDE accordingly. The CFDA can stay its NDA application for a period of up to 24 months from the date of receiving proof of court acceptance of the case, but the CDE can continue its technical review during this period. If the parties settle or a final court decision is issued during the 24-month period, the CFDA can reject or approve the NDA applications based on the settlement agreement or the court decision. If the court does not issue any judgement after the 24-month period expires, the CFDA can approve the NDA applications.
  • Improve regulatory data protection. NDA applicants can apply for regulatory data protection along with their submissions. The length of protection ranges from 1.5 years to 10 years starting from the date of NDA issuance, according to the degree of novelty and the therapeutic areas. The CDE will not approve NDAs for the same drugs during the protection period, except if the applicants can prove that they generate their data independently.
  • Establish a “China Orange Book.” The CFDA will publish a “China Orange Book” listing all approved drugs in China. The listing will contain the registration category of the approved drugs and their active ingredients, dosage forms, specifications, MAHs, and other regulatory exclusivity entitlements (i.e., patents, new drug monitoring periods, and regulatory data protection periods).

These draft CFDA policies introduce fundamental changes to the regulatory paradigm, and will considerably reshape the China strategy of life sciences companies. Companies need to carefully review the new policies, propose comments, and monitor the legislative progress.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Ropes & Gray LLP | Attorney Advertising

Written by:

Ropes & Gray LLP

Ropes & Gray LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.